Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday?
01:04pm, Tuesday, 13'th Jan 2026
Wall Street traded timidly on Tuesday despite another benign inflation report that reinforced expectations for Federal Reserve rate cuts later this year, as a weaker-than-expected start to the earning
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story
08:15am, Tuesday, 13'th Jan 2026
Moderna is undergoing a strategic shift, prioritizing infectious disease, oncology, and rare diseases to achieve cash break-even by 2028. 2026 is pivotal, with multiple oncology catalysts—especially
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10:26pm, Monday, 12'th Jan 2026
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Moderna expects 2025 revenue of $1.9B, above guidance
12:49pm, Monday, 12'th Jan 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously communicated guidance of $1.6 to $2 billion. Th
Moderna Stock Rises. Revenue in 2025 Will Be Higher Than Midpoint of Guidance.
08:51am, Monday, 12'th Jan 2026
Moderna also reiterates its expectations for revenue growth of up to 10% in 2026.
Moderna expects 2025 revenue of $1.9B, above guidance
07:45am, Monday, 12'th Jan 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously...
Moderna expects $1.9 billion in sales, trims costs forecast for 2025
07:12am, Monday, 12'th Jan 2026
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its previously projected $1.6 billion to $2 billion forecast but well below
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 12'th Jan 2026
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call Improves 2025 expected GAAP operating expenses by $200 million since 3Q25
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
06:51pm, Thursday, 08'th Jan 2026
In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 07'th Jan 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Moderna Stock Fights Back Against Four‑Year Curse With 20% Blastoff And A Golden Cross
09:03am, Wednesday, 07'th Jan 2026
Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% i
Pre-Market Stock Futures: The futures are trading flat on Wednesday after a second strong day for Wall Street, as the Dow Jones Industrial Average hit another record high, closing over $49,000 for the
Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock?
05:02am, Wednesday, 07'th Jan 2026
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
My Top 5 Stocks to Buy in Early 2026
04:15am, Wednesday, 07'th Jan 2026
These stocks, ranging from technology to healthcare, could add diversification to your portfolio. Four have proven their earnings strength; the fifth makes a solid recovery story bet.
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine
12:15pm, Tuesday, 06'th Jan 2026
Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.
